Literature DB >> 19651197

Levodopa delivery systems for the treatment of Parkinson's disease: an overview.

J Goole1, K Amighi.   

Abstract

This review describes the different drug delivery systems containing levodopa that are used in the treatment of Parkinson's disease. Their composition, process of preparation, advantages, disadvantages and limitations are discussed as well as the major objective in the management of Parkinson's disease according to the pathology of the disease.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19651197     DOI： 10.1016/j.ijpharm.2009.07.026

Source DB:  PubMed          Journal:  Int J Pharm        ISSN： 0378-5173            Impact factor:   5.875


  5 in total

Review 1.  Host-microbial interactions in the metabolism of therapeutic and diet-derived xenobiotics.

Authors:  Rachel N Carmody; Peter J Turnbaugh
Journal:  J Clin Invest       Date:  2014-08-08       Impact factor: 14.808

2.  The first global screening of protein substrates bearing protein-bound 3,4-Dihydroxyphenylalanine in Escherichia coli and human mitochondria.

Authors:  Sangkyu Lee; Yue Chen; Hao Luo; Andrew A Wu; Michael Wilde; Paul T Schumacker; Yingming Zhao
Journal:  J Proteome Res       Date:  2010-10-12       Impact factor: 4.466

3.  Evaluation of levodopa and carbidopa antioxidant activity in normal human lymphocytes in vitro: implication for oxidative stress in Parkinson's disease.

Authors:  Monica Colamartino; Massimo Santoro; Guglielmo Duranti; Stefania Sabatini; Roberta Ceci; Antonella Testa; Luca Padua; Renata Cozzi
Journal:  Neurotox Res       Date:  2014-10-30       Impact factor: 3.911

Review 4.  Developing a metagenomic view of xenobiotic metabolism.

Authors:  Henry J Haiser; Peter J Turnbaugh
Journal:  Pharmacol Res       Date:  2012-08-09       Impact factor: 7.658

Review 5.  Pharmacokinetics of Rytary®, An Extended-Release Capsule Formulation of Carbidopa-Levodopa.

Authors:  Aravind Mittur; Suneel Gupta; Nishit B Modi
Journal:  Clin Pharmacokinet       Date:  2017-09       Impact factor: 6.447
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.